Tirzepatide Is Now Approved in Indonesia for Weight Management: What Does This Mean for Bali?

Indonesia has officially expanded the approved medical uses of tirzepatide, bringing one of the most extensively studied weight-management medicines into a new regulatory position across the country, including Bali.

On 4 July 2026, Indonesia's National Agency of Drug and Food Control (BPOM) announced that tirzepatide had received marketing authorisation in February for treating type 2 diabetes, followed by an additional indication for weight management in July.

The announcement accompanied the Indonesian launch of a tirzepatide product at an event attended by BPOM chief Taruna Ikrar.

For Bali residents, expatriates and visitors, the development changes an important part of the conversation around prescription weight-management treatment.

Tirzepatide is no longer simply a medicine approved for weight management in other countries. It now has an approved weight-management indication in Indonesia.

But approval does not mean anyone can purchase it without a prescription, that every Bali pharmacy has it in stock, or that every person hoping to lose weight qualifies for treatment.

Understanding those distinctions is essential.

Tirzepatide is now approved for weight management in Indonesia, and that national approval applies to Bali.

BPOM's announcement confirms two regulatory milestones:

• February 2026: Marketing authorisation for treating type 2 diabetes.
• July 2026: An additional approved indication for weight management.

BPOM's product registration database identifies Mounjaro KwikPen as a registered tirzepatide medicine.

For patients in Bali, this creates a clearer regulatory basis for discussing tirzepatide as a prescription treatment for weight management rather than relying on its diabetes indication or approval in another country.

However, access remains dependent on medical assessment, legitimate pharmaceutical supply and the availability of the registered product.

BPOM's announcement does not establish which pharmacies or clinics in Denpasar, Canggu, Seminyak or Ubud currently have stock.

Nor does it establish a standard retail price for Bali.

These are separate questions that patients need to verify through authorised healthcare providers.

Source: BPOM's official tirzepatide announcement, 4 July 2026.

The regulatory timeline is more precise than the phrase "tirzepatide is now legal in Indonesia" might suggest.

BPOM's pharmaceutical registration database records the initial marketing authorisation for Mounjaro KwikPen on 11 February 2026.

The registration history for the product also records a new indication approved on 2 July 2026.

Two days later, BPOM publicly announced the expansion and confirmed that weight management had been added to the medicine's approved uses.

Indonesia's tirzepatide approval timeline

Source: BPOM Mounjaro KwikPen registration history.

This matters because regulatory approval is specific to a medicine and its authorised indications.

It is not a blanket approval for every product advertised as tirzepatide.

A registered Mounjaro KwikPen product is not automatically equivalent to an unregistered vial sold online, a preparation supplied by an informal peptide vendor, or a product imported without following applicable requirements.

The approved product, its registration details and its official prescribing information remain the relevant reference points.

The word peptide is used across very different categories of products.

Some peptides are established prescription medicines supported by extensive human clinical trials.

Others remain experimental compounds with little reliable evidence of effectiveness or safety in humans.

Tirzepatide belongs to the first category.

It is a prescription medicine developed through a substantial clinical research programme and evaluated by medicines regulators.

By contrast, compounds such as BPC-157 and TB-500 have not established comparable clinical evidence for their commonly promoted recovery-related uses.

This distinction is particularly important in wellness markets, where approved medicines and experimental research peptides may be discussed together.

BPOM's approval of tirzepatide does not extend to other peptides.

For more context, see our article on the Wolverine stack and the evidence behind BPC-157 and TB-500.

Tirzepatide acts on two hormone receptors involved in metabolic regulation.

The hormones are:

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).

Both are involved in the body's response to food.

Tirzepatide activates receptors associated with these hormones, helping regulate blood glucose and influencing appetite and food intake.

BPOM explains that tirzepatide can increase insulin secretion, suppress glucagon, improve insulin sensitivity and delay gastric emptying.

The medicine's effects on appetite and energy intake contribute to its role in weight management.

It is commonly described as a dual GIP and GLP-1 receptor agonist.

This is different from semaglutide, which acts as a GLP-1 receptor agonist.

Both are established medicines, but they have different pharmacological profiles and should not be treated as interchangeable products.

BPOM noted in its July announcement that it had also granted marketing authorisations for medicines containing semaglutide and liraglutide with related therapeutic indications.

The addition of tirzepatide therefore expands Indonesia's approved treatment options rather than introducing the country's first medicine in this general category.

Tirzepatide's weight-management approval is supported by considerably stronger evidence than the anecdotal reports commonly associated with experimental peptides.

One of its landmark studies was SURMOUNT-1, published in the New England Journal of Medicine in 2022.

The trial enrolled 2,539 adults with obesity, or overweight accompanied by at least one weight-related complication.

Participants with diabetes were excluded from this particular trial.

Researchers randomly assigned participants to tirzepatide or placebo and followed them for 72 weeks.

All groups also received lifestyle intervention.

The primary outcomes included percentage change in body weight and the proportion of participants achieving a reduction of at least 5%.

What happened in the SURMOUNT-1 trial?

These figures describe trial results, not recommended doses or predicted outcomes for individual patients.

The trial also found that 85% to 91% of participants assigned to tirzepatide achieved a body-weight reduction of at least 5%, compared with approximately 35% of participants receiving placebo.

The findings provide strong evidence that tirzepatide can produce clinically meaningful weight reduction in appropriately selected adults.

However, results varied between participants, and the trial population does not represent every person who might seek treatment.

The study was also funded by Eli Lilly, the medicine's manufacturer.

Source: Jastreboff et al., Tirzepatide Once Weekly for the Treatment of Obesity, NEJM, 2022.

Does this mean someone in Bali should expect to lose 20% of their weight?

No.

The often-quoted figure of approximately 21% represents the average result in one particular trial group under controlled study conditions.

It is not a guaranteed outcome.

Individual responses depend on several factors, including underlying health conditions, treatment tolerability, adherence and the broader clinical management plan.

The SURMOUNT-1 trial also excluded people with diabetes. Its results should not automatically be applied to patients with different medical characteristics.

The important finding is that tirzepatide has demonstrated substantial weight-management effects in controlled human research.

That is different from promising every patient a particular result.

The approval is a national regulatory development, but its practical consequences depend on how healthcare is delivered locally.

For someone living in Denpasar, Canggu, Seminyak, Sanur or Ubud, there are several important implications.

1. Weight management is now an approved indication in Indonesia

Before July 2026, BPOM's initial authorisation concerned type 2 diabetes.

The additional approval means that weight management is now a recognised indication within Indonesia's medicines regulatory framework.

This gives clinicians a clearer basis for considering tirzepatide within appropriate weight-management care.

It does not mean that every request for weight loss meets the approved clinical criteria.

The relevant eligibility requirements must be checked against the Indonesian-approved product information.

2. A medical assessment remains necessary

BPOM has explicitly stated that tirzepatide should be used according to a doctor's prescription and under medical supervision.

A healthcare professional needs to evaluate whether treatment is appropriate in the context of a patient's weight, medical history, other medicines and potential risks.

Weight-management treatment is not simply a matter of obtaining a particular medication.

BPOM also emphasises that managing metabolic disease requires a broader approach, including appropriate nutrition, physical activity, stress management and adequate sleep.

For people seeking care in Bali, the practical starting point is a consultation with a qualified healthcare professional rather than a product advertised through social media.

3. Local availability still needs to be confirmed

BPOM's announcement confirms national marketing authorisation.

It does not provide a verified inventory of Bali pharmacies, clinics or hospitals carrying tirzepatide.

A product can have marketing authorisation without being continuously available at every pharmacy.

Distribution arrangements, supply and individual pharmacy stock are separate matters.

Patients should not assume that a medicine advertised elsewhere in Indonesia will necessarily be available immediately in Bali.

Likewise, an online listing does not establish that a product is registered, genuine or available through an authorised supply channel.

4. Approval does not establish a fixed Bali price

BPOM did not publish an official Bali retail price in its July announcement.

It would therefore be misleading to present a particular price as the standard cost of tirzepatide in Bali without current, verifiable pharmacy information.

Patients considering long-term treatment should discuss expected ongoing costs with their healthcare provider and dispensing pharmacy.

A single advertised price may not represent the full cost of consultations, follow-up care or continued treatment.

Indonesia's national approval is relevant to residents and visitors, but it does not create an unrestricted right to purchase the medicine.

For expatriates living in Bali, access depends on the same fundamental considerations as for other patients: medical assessment, an appropriate prescription and legitimate product availability.

For tourists, the situation may involve additional practical questions.

Someone visiting Bali for a short holiday may need to consider continuity of care, follow-up arrangements and whether their treatment can be appropriately managed during travel.

A prescription issued in another country should not be assumed to be automatically valid for dispensing in Indonesia.

Similarly, BPOM's domestic marketing authorisation does not by itself establish the rules for personally importing medication through an airport.

Travellers carrying prescription medicines should verify applicable requirements with Indonesian customs and relevant authorities before travelling.

This is especially important when travelling with injectable medicines that have product-specific storage requirements.

Approval for sale within Indonesia and permission to bring medicine across the border are separate regulatory questions.

One of the practical benefits of BPOM registration is that patients have an official way to verify a medicine's regulatory identity.

Indonesia's medicines regulator operates the Cek BPOM database, which allows consumers to check registered products.

The official pharmaceutical registration portal also lists Mounjaro KwikPen and its registration history.

BPOM recommends a consumer-safety approach known as Cek KLIK.

The four checks are:

A registration number alone is not conclusive proof that a particular physical package is genuine.

Patients should also use legitimate healthcare and pharmacy channels.

BPOM advises consumers to obtain prescription-only medicines through authorised facilities and to use appropriately licensed online pharmacy services where applicable.

A product sold through an informal social-media account should not be assumed to meet these requirements simply because its seller claims that tirzepatide is now approved.

Source: BPOM guidance on obtaining medicines through legitimate supply channels.

Tirzepatide's clinical evidence is substantial, but approval does not mean it is free from risks.

The most frequently reported adverse effects involve the gastrointestinal system.

In the SURMOUNT-1 trial, gastrointestinal adverse events were common among participants receiving tirzepatide.

Most were mild to moderate and occurred primarily during treatment escalation.

However, some participants discontinued treatment because of adverse effects.

Discontinuation due to adverse events occurred in 4.3% to 7.1% of participants across the tirzepatide groups, compared with 2.6% receiving placebo.

Beyond common digestive symptoms, official prescribing information identifies several clinically important risks.

These include severe gastrointestinal reactions, dehydration-related kidney injury, gallbladder disease, pancreatitis and serious allergic reactions.

Hypoglycaemia is another consideration, particularly when tirzepatide is used alongside certain other glucose-lowering medications.

Important safety considerations

The current US prescribing information also carries a boxed warning about thyroid C-cell tumours observed in rats.

It states that the relevance of these findings to humans is unknown.

Under US labelling, tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

US prescribing information additionally warns that tirzepatide may reduce the effectiveness of oral hormonal contraceptives because of its effects on gastric emptying.

These details come from US prescribing information and should not be mistaken for a complete reproduction of Indonesia's locally approved label.

Clinicians and patients in Bali should consult the Indonesian product information for the medicine being prescribed.

Source: US FDA-approved Zepbound (tirzepatide) prescribing information, revised August 2026.

For a closer look at urgent warning signs, read When a Peptide Side Effect Becomes a Medical Emergency.

Not as a whole.

BPOM's decision concerns tirzepatide and the specific medicinal products and indications it has authorised.

It does not validate every injectable peptide marketed for fat loss, recovery, muscle growth or anti-ageing.

This distinction is particularly relevant when products are promoted alongside approved medicines.

A seller might describe an experimental peptide as similar to tirzepatide or suggest that BPOM's approval signals broader acceptance of peptide therapies.

That would be an unsupported interpretation.

Each medicine must be evaluated according to its own evidence, quality and regulatory status.

The difference can be summarised simply:

An approved peptide medicine has undergone regulatory evaluation for specified uses. An experimental research peptide has not necessarily demonstrated that it is safe or effective for human treatment.

For example, BPC-157's increasing popularity has been documented in recent healthcare-record research, but it does not have an FDA-approved therapeutic indication.

Our investigation of the 33-fold increase in documented BPC-157 use explores why popularity and clinical evidence must be considered separately.

Indonesia's tirzepatide approval should therefore be understood as a specific pharmaceutical development, not a blanket endorsement of the wider peptide market.

Several questions remain unanswered by BPOM's announcement.

The agency confirmed the approval dates, mechanism of action and expanded therapeutic indications.

It did not publish a detailed Bali-specific account of how the medicine would be distributed or accessed.

Consequently, the announcement alone cannot establish:

• Which Bali pharmacies currently stock the registered product.
• Whether particular private clinics have legitimate access to it.
• What patients will pay at different dispensing facilities.
• Whether insurance policies will cover weight-management treatment.
• Whether a foreign prescription can be accepted by a particular healthcare provider.
• Whether every formulation advertised online is registered in Indonesia.

These questions require separate verification.

In particular, the existence of a national marketing authorisation should not be used as evidence for unverified claims about clinic availability, product pricing or import permissions.

Is tirzepatide approved in Indonesia in 2026?

Yes.

BPOM granted marketing authorisation for treating type 2 diabetes in February 2026 and approved an additional weight-management indication in July 2026.

The agency confirmed both developments in its announcement dated 4 July 2026.

Is Mounjaro approved for weight loss in Bali?

BPOM's registration database identifies Mounjaro KwikPen as a registered tirzepatide medicine, with a new indication approved on 2 July 2026.

Indonesia's national approval applies to Bali.

However, patients must still meet the relevant medical criteria and obtain appropriate clinical supervision.

Can I buy tirzepatide without a prescription in Bali?

Tirzepatide is a prescription medicine.

BPOM explicitly states that treatment should take place according to a doctor's prescription and under medical supervision.

Its weight-management approval does not make it an over-the-counter product.

How much does Mounjaro cost in Bali?

BPOM's July 2026 announcement does not establish a standard Bali retail price.

Prices and availability should be verified with legitimate pharmacies and healthcare providers.

Unverified online advertisements should not be treated as authoritative pricing information.

Is tirzepatide available in Canggu, Seminyak or Ubud?

The national approval applies throughout Indonesia, including these areas of Bali.

However, BPOM's announcement does not confirm stock at individual pharmacies or clinics.

Local availability must be checked separately.

Is tirzepatide the same as semaglutide?

No.

Both are medicines used in metabolic disease management, but tirzepatide activates GIP and GLP-1 receptors, while semaglutide is a GLP-1 receptor agonist.

They are distinct medicines with their own approved indications and prescribing information.

Can tourists bring tirzepatide into Indonesia?

Indonesia's approval for domestic marketing does not automatically establish personal-import permissions for travellers.

Visitors should verify the applicable rules with Indonesian customs and relevant authorities before travelling with prescription medication.

They should also obtain professional advice about continuity of care and the storage requirements of their particular product.

Is tirzepatide safer than research peptides?

Tirzepatide has a substantially more developed human clinical evidence base and an established regulatory framework for its approved uses.

Many experimental peptides lack comparable safety and effectiveness data.

However, tirzepatide still carries clinically important risks, and the availability of stronger evidence does not mean it is appropriate for everyone.

Indonesia's July 2026 approval represents a meaningful change for people considering prescription weight-management treatment in Bali.

Tirzepatide now has an approved weight-management indication in Indonesia, alongside its earlier approval for type 2 diabetes.

This is supported by substantial human clinical evidence, including a large randomised trial demonstrating clinically meaningful average weight reduction.

For Bali residents and visitors, however, the regulatory milestone should not be confused with unrestricted access.

Treatment remains subject to medical assessment, prescription requirements, legitimate pharmaceutical supply and the relevant product information.

The approval also does not establish which local clinics have stock, what the medicine costs or whether a particular traveller can import it.

The key development is that weight management is now an officially recognised indication for tirzepatide in Indonesia.

The next question for an individual patient is not simply where to find it in Bali, but whether it is medically appropriate, available through a legitimate channel and supported by suitable ongoing care.

1. Badan Pengawas Obat dan Makanan (BPOM), 4 July 2026. BPOM Dorong Akses Terapi Inovatif untuk Penanganan Penyakit Metabolik dengan Zat Aktif Tirzepatide. Official announcement confirming the February diabetes approval and July weight-management indication. Read the BPOM announcement.

1. BPOM Directorate of Drug Registration, 2026. Mounjaro KwikPen Assessment Report and Registration History. Official registration records documenting the initial marketing authorisation and subsequent indication expansion. View the product registration.

1. Jastreboff AM et al., 2022. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387, 205–216. DOI: 10.1056/NEJMoa2206038. Read the SURMOUNT-1 trial.

1. US Food and Drug Administration, August 2026. Zepbound (tirzepatide) Prescribing Information. Official US labelling describing contraindications, adverse reactions, warnings and precautions. Read the prescribing information.

1. Badan Pengawas Obat dan Makanan (BPOM). Guidance on Obtaining Medicines Through Authorised Supply Channels. Indonesian consumer guidance concerning prescriptions, licensed pharmacies and product verification. Read the BPOM guidance.

Medical Disclaimer

This article is for educational and research-information purposes only. It does not provide medical advice, diagnosis or treatment recommendations. Tirzepatide is a prescription medicine with specific approved indications, contraindications and potential adverse effects. Regulatory approval does not mean treatment is appropriate for every individual. Consult a qualified healthcare professional and refer to the Indonesian-approved product information for personal medical decisions.